close icon-linkedin icon-twitter icon-facebook icon-mail icon-google-plus icon-search icon-phone icon-instagram
What are you looking for?
Narek Manukjan

Narek Manukjan

Trainee patent attorney
As a trainee patent attorney at NLO, I am passionate about providing tailored services to protect clients’ inventions and intellectual property. My wide range of expertise in cellular and molecular biology allows me to work with clients from different backgrounds and provide specific advice on strategies to protect your valuable intellectual property.


  • Antibody
  • Biotechnology
  • Pharma
  • Gene therapy
  • Medical Technology
  • Oligonucleotide
  • Medicines

I completed my PhD as a neurobiologist and obtained a double degree from Maastricht University (NL) and the University of Birmingham (UK). My research focused on the molecular interaction between different brain cell types in relation to vascular dementia. I conducted fundamental research in both in vitro and in vivo models. I also investigated the potential of modulating small molecules as a possible therapeutic strategy and identified novel biomarkers for the early diagnosis of vascular dysfunction in the brain. 

I strive to protect the rights and intellectual properties of the innovators that shape inventions

I believe that conducting fundamental research is essential for innovation and drives the development of novel therapies. In doing so, I strive to protect the rights and intellectual properties of the innovators that shape these inventions. My expertise will enable me to have an in-depth understanding of the technical background and importance of clients’ inventions, focusing on protecting the client’s needs and rights. 

Training & Education

  • PhD Neuroscience and cardiovascular research, Maastricht University (NL) and University of Birmingham (UK) [2024]
  • MSc Cognitive and Clinical Neuroscience, Maastricht University [2018]
  • BSc Biomedical Sciences, Maastricht University [2016]


  • Wnt7a Decreases Brain Endothelial Barrier Function Via β-Catenin Activation. Mol Neurobiol. 2023 Dec 26. doi: 10.1007/s12035-023-03872-0. Epub ahead of print. PMID: 38147228.
  • Hypoxic oligodendrocyte precursor cell-derived VEGFA is associated with blood-brain barrier impairment. Acta Neuropathol Commun. 2023 Aug 7;11(1):128. doi: 10.1186/s40478-023-01627-5. PMID: 37550790; PMCID: PMC10405482.
  • A Systematic Review of WNT Signaling in Endothelial Cell Oligodendrocyte Interactions: Potential Relevance to Cerebral Small Vessel Disease. Cells. 2020 Jun 25;9(6):1545. doi: 10.3390/cells9061545. PMID: 32630426; PMCID: PMC7349551.